Abstract YO13
Case summary
Background: Immunoglobulin G4 (IgG4)-related disease is a rare immune-mediated fibroinflammatory condition, characterized by infiltration of IgG4 positive plasma cells and storiform fibrosis. The clinical presentation included fibrosis of affected organs and pseudotumor formation occasionally mimic malignancy.
Aims: To present a case of IgG4-related kidney disease mimicking renal cell carcinoma
Method: Case report
Result: 53-year-old male with an unremarkable previous medical history presented with painless gross hematuria, fever and anemic symptom for 3 months. Laboratory tests showed microcytic anemia, normal creatinine levels and numerous white blood cells in urine. CT chest and abdomen revealed an infiltrative heterogenous hypoenhancing lesion at right kidney size 7.5 x7.9 x8.5cm, a hypoenhancing lesion in hepatic segment IVa/VIII size 6.8x3.8 cm, diffuse intraabdominal lymph node enlargement up to 1.8 cm and multiple lung nodules. The initial clinical and radiologic findings were highly suggestive of malignancy. The differential diagnosis is renal cell carcinoma and lymphoma. Liver biopsy was performed and shown chronic inflammation and fibrosis. Subsequently renal biopsy was done and revealed chronic interstitial nephritis, focal interstitial fibrosis and prominent plasma cell infiltration. Immunohistochemistry from renal biopsy revealed positive for CD20, CD3, CD38, CD138, IgG (210 cells/HPF) and IgG4/IgG-positive cell ratio was 54%. In situ hybridization for kappa and lambda light chain showed polyclonal plasma cell with kappa to lambda ratio of 4:1. Serum IgG4 level was more than 5,840 mg/dL. These findings made diagnosis of IgG4 related kidney disease. Prednisolone 60 mg/day was given and gradually reduced to 10 mg five months thereafter. After 3 months of therapy, a follow-up CT scan showed decrease size of right renal mass to 6.1 x7.3 x6.2 cm, nearly complete resolved of liver lesion and some prior pulmonary nodules.
Conclusion: IgG4 related kidney disease can present with pseudotumor and can be misdiagnosed as a malignant tumor. Awareness of this condition and proper investigation including histopathology and serum IgG4 level should be considered in case of highly suggestive patient.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
467P - The free-circulating mtDNA copies number in plasma of patients with NSCLC
Presenter: Olga Bulgakova
Session: Poster display session
Resources:
Abstract
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract